Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Patients are preselected for CDKN2A and/or CDKN2B abnormalities - - Safety and efficacy data to be reported at an upcoming oncology medical conference - BERKELEY HEIGHTS, N.J., Sept. 25, 2024 (GLOBE ...
SEBI Launches Outreach Cell To Help FPIs Seamlessly Access Indian securities Market
The Securities and Exchange Board of India (SEBI) on Wednesday launched a dedicated Foreign Portfolio Investor (FPI) outreach ...
Targeted Oncology2d
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...
The Scientist19d
Introducing a New Version of the Cell Cycle
This sequential expression followed the phases of the traditional cell cycle: G0/G1 (the cell grows larger), S (the cell replicates its DNA), and G2/M (the cell prepares for division and then splits).
Finanznachrichten5d
DelveInsight Business Research, LLP: Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight
The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor ... This overexpression contributes to tumor cell proliferation through cell cycle dysregulation, ...
Coherent Awarded Phase 3 of IARPA Resilience Program for High-Energy Rechargeable Lithium-Sulfur Batteries
PITTSBURGH, Sept. 12, 2024 (GLOBE NEWSWIRE) -- (NYSE: COHR), a leading provider of advanced engineered materials, announced ...
Scientific American8d
Researchers Seek New Solutions to Ease Sickle Cell’s Extreme Pain
Sickle cell disease causes severe pain that’s hard to treat, but researchers are finding new ways to offer relief ...